Amyl Therapeutics
Liège
About Amyl Therapeutics
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-╬▓ (A╬▓), Tau, and ╬▒-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $100K – $500K
- Total funding: $34.4M
- Funding stage: Early Stage Venture
- Last round: Grant (Nov 2023)
- Website: amyltx.com
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/amyl-therapeutics-33039 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.